Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Liquidia Corporation

< Previous 1 2 Next >
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia to Present at the Stifel 2024 Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia to Present at Upcoming Investor Conferences
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Announces Updates to Operations Leadership
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.